Key result
Paraventricular nucleus inactivation attenuates reflex hypertensive responses by ~34% in spontaneously hypertensive rats.
Why the study?
To test whether inactivation of the PVN attenuates the elevated reflex response to epicardial bradykinin in the SHR, and whether ionotropic PVN glutamate receptors mediate this reflex.
Does inactivation of the paraventricular nucleus attenuate the cardiogenic sympathetic afferent reflex in spontaneously hypertensive rats?
Does inactivation of the paraventricular nucleus attenuate the cardiogenic sympathetic afferent reflex in spontaneously hypertensive rats?
Glutamatergic activity within the paraventricular nucleus contributes to the augmented cardiogenic sympathetic afferent reflex observed in spontaneously hypertensive rats.
Supports PVN glutamatergic drive in hypertensive sympathetic reflexes; hypothesis-generating with no clinical translation yet.
BACKGROUND: Myocardial ischemia causes the release of bradykinin, which stimulates cardiac afferents, causing sympathetic excitation and chest pain. Glutamatergic activation of the paraventricular hypothalamic nucleus (PVN) in the spontaneously hypertensive rat (SHR) drives elevated basal sympathetic activity. Thus, we tested the hypothesis that inactivation of the PVN attenuates the elevated reflex response to epicardial bradykinin in the SHR and that ionotropic PVN glutamate receptors mediate the elevated reflex. METHODS: We recorded the arterial pressure and renal sympathetic nerve activity (RSNA) response to epicardial bradykinin application in anesthetized SHR and Wistar Kyoto (WKY) rats before and after PVN microinjection of GABA A agonist muscimol or ionotropic glutamate receptor antagonist kynurenic acid. RESULTS: Muscimol significantly decreased the arterial pressure response to bradykinin from 180.4 ± 5.8 to 119.5 ± 6.9 mmHg in the SHR and from 111.8 ± 7.0 to 84.2 ± 8.3 mmHg in the WKY and the RSNA response from 186.2 ± 7.1 to 142.7 ± 7.3% of baseline in the SHR and from 201.0 ± 11.5 to 160.2 ± 9.3% of baseline in the WKY. Kynurenic acid significantly decreased the arterial pressure response in the SHR from 164.5 ± 5.0 to 126.2 ± 7.7 mmHg and the RSNA response from 189.9 ± 13.7to 168.5 ± 12.7% of baseline but had no effect in the WKY. CONCLUSION: These results suggest that tonic PVN activity is critical for the full manifestation of the CSAR in both the WKY and SHR. Glutamatergic PVN activity contributes to the augmented CSAR observed in the SHR.
No takes yet. Share an insight, caveat, or question.
Zahner et al. (2023) studied Spontaneously hypertensive rat (SHR) model of neurogenic hypertension (n=72). Paraventricular nucleus microinjection of muscimol or kynurenic acid vs. Pre-treatment baseline and vehicle was evaluated on Arterial pressure response to epicardial bradykinin in SHR (p=<0.05). Inactivation of the paraventricular nucleus with muscimol or kynurenic acid significantly attenuated the elevated arterial pressure and sympathetic reflex response to epicardial bradykinin in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: